Program

In-person AND virtual! – We pioneered a new conference format that connected in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR pushed the boundaries of innovation to design an event that worked in today’s quickly changing environment.

While the live portion of ISPOR Europe 2022 is now over, you may still register for the virtual only portion. Gain access to nearly all in-person and virtual content available on-demand as well as ISPOR’s robust virtual platform which includes networking and posters. Register today!

On-demand session recordings as well as virtual posters and networking will be available through 9 December 2022. 

Download the program guide

Rate of Complete Spectacle Independence With a Trifocal IOL: A Systematic Literature Review and Meta-Analysis

Speaker(s)

Zhu D1, Ren K2, Mills K3, Lemp-Hull J4, Dhariwal M4, Srivastava T5
1NVISION Eye Centers, Rowland Heights, CA, USA, 2University of Sheffield, Sheffield, NYK, UK, 3Alcon Vision LLC, Ramsey, MN, USA, 4Alcon Vision LLC, Fort Worth, TX, USA, 5ConnectHEOR, London, LON, UK

Presentation Documents

OBJECTIVES: AcrySof IQ PanOptix (TFNTXX, TFATXX) is the first trifocal IOL launched in the USA in 2019. A systematic literature review and meta-analysis was conducted to identify and pool published evidence on complete spectacle independence rate in patients with bilateral implantation of TFNTXX/TFATXX.

METHODS: PubMed was searched from Jan 2017 to Sep 2021; congress abstract databases were also searched for recent studies that are yet to be published in peer-reviewed journals. Search terms included the technology name (TFNTXX, TFATXX, PanOptix) and “spectacle independence” or “visual outcomes”. A Bayesian random effects meta-analysis was conducted, providing a pooled estimate (posterior median treatment effect and its 95% credible interval (CI)) of complete spectacle independence rate among cataract or refractive lens exchange (RLE) surgery patients. Sub-group analyses evaluated spectacle independence across different distances (near, intermediate, far).

RESULTS: Twenty-six unique clinical studies were identified (20 peer-reviewed publications, 6 congress presentations). Among patients who underwent cataract surgery with TFNTXX/TFATXX IOL, meta-analysis demonstrates complete spectacle independence rate of 91.6% (95% CI 0.87–0.96; N=13 studies). Sub-group analyses of pooled spectacle independence rates at each focal point of near, intermediate, and far among cataract surgery patients were 89.6%, 96.3%, and 95.9%, respectively (N=13). Including studies with all patient populations, i.e. patients who underwent cataract or RLE surgery with TFNTXX/TFATXX IOL, complete spectacle independence rate further improved to 92.8% (95% CI 0.89–0.96; N=19).

CONCLUSIONS: This meta-analysis demonstrates at least 9 out of 10 patients receiving TFNTXX/TFATXX IOL for cataract surgery can be expected to achieve complete spectacle independence. This study provides informative data for clinicians and patients to feel confident in the use of TFNTXX/TFATXX as a trifocal IOL with high rate of complete spectacle independence.

Code

MT2

Topic

Medical Technologies, Patient-Centered Research, Study Approaches

Topic Subcategory

Medical Devices, Meta-Analysis & Indirect Comparisons, Patient-reported Outcomes & Quality of Life Outcomes

Disease

SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), STA: Medical Devices